What are the stocks in the listed biopharmaceutical sector?
Leading biopharmaceutical stocks are companies with core biopharmaceutical technology and market competitiveness. With the growth of medical and health needs and technological advances, the biopharmaceutical industry has great potential for development. The following editorial brings listed companies what stocks are in the biopharmaceutical sector, which is of great benefit to all of you, take a look together.
What are the stocks in the listed biomedical sector
Tiantan Bio, Guangshengtang, Dongbao Bio, Zhenghai Bio, Lexin Medical and so on.
1, Tiantan Biological
The full name of the company is Beijing Tiantan Biological Products Company Limited (referred to as "Tiantan Biological"), and its listed stock is Tiantan Biological (600161). It is an enterprise engaged in the research, production and operation of vaccines, blood preparations, diagnostic supplies and other biological products, and was listed on the Shanghai Stock Exchange in 1998 by the Beijing Institute of Biological Products, and now the controlling shareholder is China National Biotechnology Corporation.
2, Guangshengtang
The company's full name is Fujian Guangshengtang Pharmaceutical Co. Its listed stock is Guangshengtang (300436), is a collection of drug research and development, production, sales in one of the modern pharmaceutical enterprises, GMP certification of modern factories.
3, Dongbao Biological
The company's full name is Baotou Dongbao Biotechnology Co., Ltd. was founded in 1997, its listed stock is Dongbao Biological (300239), is specialized in the production of gelatin and extended products collagen production enterprises. State-level high-tech enterprises, Inner Mongolia private enterprises top 50, in 2011 in Shenzhen A shares successfully listed. Mainly engaged in gelatin series products, collagen and calcium phosphate.
What are the leading biomedical medical stocks
The leading biomedical stocks are the following:
1, China Heng Group 600252
2, Zhejiang Longsheng 600352
3, Dongyangguang 600673
4, Yu Heng pharmaceuticals 002437
5, China Baoan 000009
6, Tonghua Dongbao 600867
7, Shanghai Medical Insurance 601607
8, Fosun Pharmaceuticals 600196
9, Huabang Health 002004
10, Jiangsu Sunshine 600220
Biological Medicine Board strong>What are the leading stocks in the biomedical sector
The biomedical sector is one of the hot industries in the current capital market, and there are a number of listed companies with strong competitiveness and performance.
The stocks that are the leading ones mainly include: United Amino Acids, Hengrui Medicine, WuXi Biotechnology, Myriad Medical and so on. These companies in the field of biopharmaceuticals, medical diagnostics, health services and other areas of high technology content and innovation, market prospects, investors can pay attention to these companies with leading potential, according to the actual situation of prudent investment.
What are the leading stocks of listed pharmaceutical companies
The leading stocks of listed pharmaceutical companies are Tencent Holdings Limited, Pharmaceuticals Biotechnology, China Biopharmaceuticals.
1, Tencent Holdings Limited (00700.HK): Tencent's pharmaceutical subsidiary Tencent Healthcare is one of China's leading Internet healthcare platforms, and is one of the leading companies in the pharmaceutical industry.
2. WuXi Biologics (02269.HK): a biopharmaceutical company focusing on innovative drug development, is one of the largest drug development outsourcing service providers in China.
3, WuXi Biologics (02269.HK): a biopharmaceutical company focusing on innovative drug R&D and one of the largest drug R&D outsourcing service providers in China.
List of Leading Stocks for Doctors
The leading pharmaceutical and biological stocks are:Hengrui Medicine(600276), Fosun Pharmaceutical(600196), Yunnan Baiyao(000538), Xinlite(002294), Kelaiyin(002821), Aier Ophthalmology(300015), Pientzehuang(600436).
Chemical Pharmaceuticals
It is the first and leader in China's innovative drug development. It is a leading company in China's innovative drug field with complete product structure and R&D channels. It is a leader in innovative drug development. Piratinib is independently developed by the company 1. An innovative drug is the company's heavy bomb product. Piratinib has a $1.4 billion market for breast cancer indications, and future indications will be expanded to include lung and stomach cancer.
Fosun Pharma
600196
Shanghai
Biopharmaceuticals II
Fuhong Hanklin is a platform for the research and development and production of biopharmaceuticals, and owns 61.093 shares of the company, with biosimilars leading the way in China in terms of research and development strength and progress. It is expected that biosimilars such as rilituximab, trastuzumab and adalimumab will be approved in the next three years. The biosimilars market is large, with many heavyweight products, high barriers to entry and low Medicare support. In the long run, they are optimistic about the oligopoly competition model.
Yunnan Baiyao
000538
Shenzhen
Chinese Medicine II
The company is one of China's leading manufacturers of proprietary Chinese medicines. It is one of the top 50 proprietary Chinese medicine companies. The company's main products include Yunnan Baiyao and natural botanicals, with 19 dosage forms and more than 300 varieties, and its sales volume ranks first in Yunnan Province. At present, the company also owns Yunnan Baiyao Bulk and Yunnan Baiyao Capsules, which are national-level protected proprietary Chinese medicines.On August 18, 2017, Yunnan Baiyao was selected into the 2017 China Health Brand List and Brand Value List.
Xinlitai
002294
Small and medium-sized board
Chemical Pharmaceuticals
Shenzhen Litai Pharmaceuticals Co. Ltd. internal and external expansion, is a double force in the medical equipment ladder. The company focuses on the development of cardiovascular specialty drugs, innovative drugs and unique products. Existing patented drugs have unique advantages, forming a pyramid product structure radiating from high-end to downward. Innovative drugs are progressing well and clinical use of flucytosine is underway. The novel anti-heart failure drug S glucagon-like peptide-1-Fc injectable fusion protein has been accepted.
Most Potential Leading Biomedical Stocks
Potential leading biomedical stocks are as follows:
1. Hengrui Medicine (600276), the first share of the domestic innovative drugs. The main product lines are anti-tumor, anesthesia, contrast agents and so on. The company's return on net assets for many years to maintain more than 23%, net profit for many years to maintain a rate of growth of more than 20%. The company's R&D strength is very strong, the management team is relatively good, and the sales capacity is also very strong.
2. Aier Ophthalmology (300015), the first share of domestic ophthalmic hospital chain. Mainly to provide patients with a variety of ophthalmic diseases diagnosis, treatment and medical optometry and other ophthalmic medical services. The company's return on net assets for many years to maintain at about 20%, net profit for many years to maintain a rate of growth of more than 30%.
3. Myriad Medical (300760), the first domestic medical equipment. The main product lines are life and information support, in vitro diagnostics, medical imaging and so on. The company's return on net assets for many years to maintain more than 25%, net profit for many years to maintain a rate of growth of more than 25%.